Wednesday, 21 June 2017 16:26

An attack on candidiasis from the spleen

Activation of immune cells during candida infection Activation of immune cells during candida infection Carlos Ardavín, CNB-CSIC

An article published today in the journal Immunity describes the strategy used by cells of the innate immune system against a generalized fungal infection. The authors establish the spleen as a key organ that activates the defences responsible for terminating the Candida fungus that colonizes the whole body. The study shows the role of IL-15 in this process and opens a path to new, more effective therapies for fungal infections.

A group of scientists at the Centro Nacional de Biotecnología of the CSIC (CNB-CSIC) has detailed the defence strategy implemented by the immune system against a systemic attack by the Candida fungus. The study, published today in the journal Immunity, proposes a scenario in which the spleen acts as a headquarters in which defences are established to terminate an infection that affects the whole body.

Their research also highlights the central role of interleukin 15 (IL-15) in this battle. This molecule, which to date was not linked to fungal infections, activates the innate immune system through an interferon type I (IFN-1)-mediated mechanism. "The incorporation of these two new actors presents a promising scenario for the development of new therapies against systemic candidiasis," explains Carlos Ardavín, a CNB-CSIC researcher and lead author of the paper.

Coordinated defence between kidney and spleen

The study, carried out in mice, indicates that after detecting infection, spleen monocytes begin to produce IFN-1. This in turn induces release of IL-15, responsible for activating natural killer (NK) cells. Finally, neutrophils activated by the NK cells travel to the infection site and eradicate the fungus.

Although fungal infections pose a considerable threat, their impact on human health is less well recognized than that of other diseases. Systemic candidiasis is estimated to affect half a million people every year. It is a problem of particular importance for immunosuppressed patients, among whom it causes up to 40% mortality.

According to the researchers, multi-resistant Candida species are beginning to appear that cause increasingly severe infections; it is therefore urgent to explore new antifungal therapeutic strategies. In addition, the scientists say that effectiveness of classical treatments is limited in patients who receive immunosuppressive drugs. "The results of our research suggest that new IL 15-based therapies could be a very promising strategy against these infections," Ardavín concludes.

 

ImmunityArdavin1

Innate immune system defence strategy against Candida. / Carlos Ardavín, CNB-CSIC

 

back to top